Lifecore Biomedical (LFCR) Short Interest Ratio & Short Volume

Short interest is the volume of Lifecore Biomedical shares that have been sold short but have not yet been covered or closed out. As of June 30th, traders have sold 2,300,000 shares of LFCR short. 7.04% of Lifecore Biomedical's shares are currently sold short. Learn More on Lifecore Biomedical's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LFCR shares currently have a short interest ratio of 9.0. Learn More on Lifecore Biomedical's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.04% of Lifecore Biomedical's floating shares are currently sold short.

Lifecore Biomedical currently has issued a total of 37,030,000 shares. Some of Lifecore Biomedical's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lifecore Biomedical currently has a public float of 32,670,000 shares.

7.04% of Lifecore Biomedical's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Lifecore Biomedical: Enliven Therapeutics, Inc. (15.81%), Structure Therapeutics Inc. Sponsored ADR (13.40%), Cidara Therapeutics, Inc. (12.30%), Ardelyx, Inc. (12.17%), Praxis Precision Medicines, Inc. (9.77%), ProKidney Corp. (14.90%), Collegium Pharmaceutical, Inc. (14.13%), Akebia Therapeutics, Inc. (10.01%), Amphastar Pharmaceuticals, Inc. (11.74%), Arcus Biosciences, Inc. (17.20%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

Short selling LFCR is an investing strategy that aims to generate trading profit from Lifecore Biomedical as its price is falling. LFCR shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lifecore Biomedical occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LFCR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LFCR, twice per month. The most recent reporting period available is June, 30 2025.